Drug Profile
Brincidofovir - Chimerix/Emergent Biosolutions
Alternative Names: BCV; BCV-001; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; CMX001-129; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix; SyB-V-1901; TEMBEXALatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Brown University; Centers for Disease Control and Prevention; Chimerix; Emergent BioSolutions; National Cancer Centre (Singapore); National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA); SymBio Pharmaceuticals; University of California at San Francisco; University of Oxford
- Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Smallpox
- Phase III Cytomegalovirus infections
- Phase II/III Viral infections
- Phase II Adenovirus infections; Human polyomavirus infections
- Preclinical Epstein-Barr virus infections; Glioblastoma
- No development reported Herpes simplex virus infections; Monkeypox
- Discontinued Ebola virus infections
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Japan (IV, Infusion)
- 13 Dec 2023 Registered for Smallpox (In neonates, In infants, In children, In adults) in Canada (PO)
- 09 Dec 2023 Effiacy and adverse events data from a phase II ATHENA trial in Adenovirus infection presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)